CoImmune, MSK will collaborate on CAR-CIK therapies to treat solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CoImmune, Inc. and Memorial Sloan Kettering Cancer Center entered a license and collaboration agreement to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors.  

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login